SCHEMBL4975600

SCHEMBL4975600

CC1(C)CC(=O)Nc2cc(NC(=O)c3cc(F)cnc3Cl)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.57
TNKS2 Q9H2K2 1/20 0.57
INSR P06213 2/20 0.41
MET P08581 2/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39
CIT O14578 1/20 0.39
MAP3K7 O43318 1/20 0.39
RIPK2 O43353 1/20 0.39
STK10 O94804 1/20 0.39
MAP4K4 O95819 1/20 0.39
ABL1 P00519 1/20 0.39
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5424088 0.84 CIT (0.44) TNKSTNKS2INSRMETRARB
SCHEMBL3145019 0.80 TNKS (0.56) TNKSTNKS2INSRMETHDAC3
SCHEMBL9866488 0.79 TNKS (0.52) TNKSTNKS2HDAC3HDAC4HDAC1
SCHEMBL5426299 0.78 WEE1 (0.43)
SCHEMBL4971424 0.76 TNKS (0.46) TNKSTNKS2METCITMAP3K7
SCHEMBL9312251 0.76 TNKS (0.52) TNKSTNKS2HDAC3HDAC4HDAC1
SCHEMBL4974244 0.75 NOTUM (0.41) NPC1RAB9ASMN1; SMN2ALDH1A1GAA
SCHEMBL9313154 0.74 TNKS (0.50) TNKSTNKS2HDAC3HDAC4HDAC1
SCHEMBL9376603 0.74 BACE1 (0.52) TNKSTNKS2RARBRARGNPC1
SCHEMBL9314396 0.74 RARB (0.54) TNKSTNKS2HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US disclosed
EP-1971604-B1 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC (US) 2012-08-01 EP disclosed
EP-1971604-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Amgen Inc. (US) 2008-09-24 EP disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
WO-2007048070-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185171-A1 Compounds and methods of use VHL, PGF, PTGIS TNKS 1867/4885TNKS2 2255/4885INSR 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.